 FOSTER CITY, Calif., Jan. 03, 2022 GLOBE NEWSWIRE -- Terns Pharmaceuticals, Inc. Terns or the Company Nasdaq: TERN, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis NASH, today announced that the Companys management team will present at the following investor conferences in January: 